Kailera Therapeutics(KLRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KLRA Kailera Therapeutics

Not Yet Opened 10-19 16:00:00 EDT

11.43

+0.18

+1.60%

盘后11.43

+0.000.00%

19:30 EDT

High11.69	Low11.18	Vol896.58K
Open11.34	D1 Closing11.25	Amplitude4.53%
Mkt Cap1.48B	Tradable Cap513.46M	Total Shares129.54M
T/O10.28M	T/O Rate2.00%	Tradable Shares44.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KLRA","market":"US","secType":"STK","nameCN":"Kailera Therapeutics","latestPrice":11.43,"timestamp":1792440000000,"preClose":11.25,"halted":0,"volume":896581,"hourTrading":{"tag":"盘后","latestPrice":11.43,"preClose":11.43,"latestTime":"19:30 EDT","volume":1645,"amount":18802.35,"timestamp":1792452604899,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.015999999999999976,"floatShares":44921899,"shares":129537300,"eps":-2.254252,"marketStatus":"Not Yet Opened","change":0.18,"latestTime":"10-19 16:00:00 EDT","open":11.34,"high":11.69,"low":11.18,"amount":10284813.7932785,"amplitude":0.045333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.254252,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792483200000},"marketStatusCode":0,"adr":0,"listingDate":1776398400000,"exchange":"NASDAQ","adjPreClose":11.25,"preHourTrading":{"tag":"盘前","latestPrice":11.31,"preClose":11.25,"latestTime":"09:29 EDT","volume":1476,"amount":16586.220852000002,"timestamp":1792416599987,"change":0.06,"changeRate":0.005333,"amplitude":0.019307},"postHourTrading":{"tag":"盘后","latestPrice":11.43,"preClose":11.43,"latestTime":"19:30 EDT","volume":1645,"amount":18802.35,"timestamp":1792452604899,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.734122,"impliedVol":0.32,"impliedVolPercentile":0.0833},"requestUrl":"/m/hq/s/KLRA/tweets","defaultTab":"tweets","newsList":[{"id":"2675591268","title":"Breakingviews-China Biotech's Ingenuity Extends to Dealmaking","url":"https://stock-news.laohu8.com/highlight/detail?id=2675591268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675591268?lang=en_us&edition=fundamental","pubTime":"2026-10-16 20:00","pubTimestamp":1792152000,"startTime":"0","endTime":"0","summary":"RPT-BREAKINGVIEWS-China biotech's ingenuity extends to dealmakingHONG KONG, Oct 16 (Reuters Breakingviews)-Long gone are the days when Big Pharma scoffed at the reliability of China's clinical trials.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261016:nL6N4620FP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345777659.USD","LU0405327148.USD","BK1574","LU0971552830.HKD","LU2355687059.USD","LU1064130708.USD","LU0321505868.SGD","LU1267930573.SGD","LU2433249047.HKD","LU2114397693.USD","IE0034235188.USD","OZEM","LU1153585028.USD","LU1019634622.SGD","LU0345777147.USD","02162","LU0225771236.USD","AZN.UK","600276","LU0047473722.SGD","LU1989771016.USD","03165","LU1267930490.SGD","LU0266013472.USD","LU1196032939.SGD","LU1104425308.USD","LU0985481810.HKD","LU2495084118.USD","LU1273509221.SGD","LU1302929846.USD","LU0661504455.SGD","LU1228905037.USD","LU1481599808.USD","BK1587","LU0969580561.USD","KLRA","IE0009355771.USD","LU1003077747.HKD","GSK.UK","LU0289739699.SGD","LU1015430645.USD","LU2023251221.USD","IE00B2B36J28.USD","LU0949170426.SGD","IE00BQJZX424.USD","LU2324357040.USD","LU0708994859.HKD","LU0171293334.USD","LU1829250122.USD","LU1781817850.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674861959","title":"U.S. Small Caps Move Upward; Kailera Therapeutics Leads Increases","url":"https://stock-news.laohu8.com/highlight/detail?id=2674861959","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674861959?lang=en_us&edition=fundamental","pubTime":"2026-10-10 04:20","pubTimestamp":1791577200,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of small-cap companies gained Friday, as the Russell 2000 Index gained 0.5%, and the S&P Small Cap 600 Index was up 0.1%.Among companies with a market value of $1 billion to $6.7 billion, Kailera Therapeutics Inc. was the best performer during the session, surging 16%, followed by Fastly Inc. Cl A, which jumped 16%. Novavax Inc. shares surged 16%, Absci Corp. surged 14%, and shares of PicS N.V. surged 14%.Chaince Digital Holdings Inc. was the biggest laggard, dropping 21%, followed by shares of Cardinal Infrastructure Group Inc., which dropped 16%. Shares of Alignment Healthcare Inc. dropped 13%, Eos Energy Enterprises Inc. shares tumbled 8.9%, and Avient Corp. tumbled 7.8%.Major stock indexes in the U.S. rose Friday with the Nasdaq Composite Index gaining 0.6%. Meanwhile, the S&P 500 Index added 0.6%, and the Dow Jones Industrial Average increased 0.8%.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA","OZEM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672592167","title":"Kailera Therapeutics announces positive results from several presentations","url":"https://stock-news.laohu8.com/highlight/detail?id=2672592167","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672592167?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:55","pubTimestamp":1790852154,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (KLRA) announced Phase 1 data for ribupatide injection, a GLP-1/GIP receptor dual agonist currently advancing through global P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-announces-positive-results-from-several-presentations-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kailera-therapeutics-announces-positive-results-from-several-presentations-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRA","BK4139","JDOC","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672599567","title":"Kailera Reports Phase 1 Data Showing Ribupatide Injection Exposure Similar Across Abdomen, Arm, Thigh Sites","url":"https://stock-news.laohu8.com/highlight/detail?id=2672599567","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672599567?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:45","pubTimestamp":1790851544,"startTime":"0","endTime":"0","summary":"Kailera reports Phase 1 data showing ribupatide injection exposure similar across abdomen, arm, thigh sitesKailera highlighted Phase 1 ribupatide injection data already presented at EASD 2026.Study su","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL1dD6V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0229494975.USD","IE00BN0W2T93.GBP","LU2088747725.USD","LU0886674414.USD","IE00B1G9TL16.USD","NDAQ","SG9999010052.SGD","LU2210149790.SGD","LU2095319765.USD","BCDF","SG9999014039.USD","IE00BKPKM429.USD","LU1316543674.SGD","LU1539696804.USD","SUHJY","00016","SG9999014021.USD","OZEM","SG9999002463.SGD","LU1163227496.USD","IE00BN0W2W23.USD","KLRA","BK4588","IE00BQXX3C00.GBP","IE00BSPPW651.USD","BK1216","LU0096374516.USD","LU2088748293.HKD","LU0315179316.USD","IE00BQXX3F31.USD","BK4585","SG9999004220.SGD","03145","03121","LU2226123227.USD","IE00B64PRP62.GBP","SG9999009997.SGD","IE00BN0W2V16.EUR","BK1521","LU1504937902.USD","BK4139","SG9999010078.USD","LU2210150020.SGD","80016","LU0224508324.USD","IE00BGHQF748.EUR","SG9999014005.SGD","LU2088748020.USD","LU2088747998.USD","LU2226123490.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672759490","title":"Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2672759490","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672759490?lang=en_us&edition=fundamental","pubTime":"2026-10-01 18:45","pubTimestamp":1790851500,"startTime":"0","endTime":"0","summary":"- New Phase 1 data highlight flexibility of injection site for ribupatide injection - Four additional oral presentations from Hengrui Pharma add to the clinical evidence behind Kailera's pipeline WALT","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/01/3372706/0/en/kailera-therapeutics-presents-new-clinical-data-at-easd-2026-annual-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","HYLG","OZEM","BK4139","JDOC","GDOC","NVIB","KLRA","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671851997","title":"Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671851997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671851997?lang=en_us&edition=fundamental","pubTime":"2026-09-30 23:20","pubTimestamp":1790781616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kailera Therapeutics, Inc. (KLRA) and Immunome (IMNM...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kailera-therapeutics-inc-klra-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kailera-therapeutics-inc-klra-and-immunome-imnm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XLV","XBI","LU0029874061.USD","BK4137","BK4139","KLRA","BK4585","BK4563","BK4581","HCSG","LABU","IMNM","OZEM","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671526206","title":"Kailera Therapeutics Completes Enrollment in KaiNETIC Phase 3 Trials of Obesity Drug Ribupatide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2671526206","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671526206?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:04","pubTimestamp":1790766276,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics completes enrollment in KaiNETIC Phase 3 trials of obesity drug ribupatide injectionKailera Therapeutics completed enrollment in its global Phase 3 KaiNETIC program testing once-w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL5QjnhS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014005.SGD","SG9999014021.USD","BCDF","OZEM","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","LU2095319765.USD","BK4112","BK4585","BK4139","IE00BQXX3C00.GBP","BK4588","IE00BQXX3D17.EUR","SG9999014039.USD","KLRA","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671206861","title":"Kailera Therapeutics - Topline Data from Kainetic Phase 3 Trials Expected in Mid-2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2671206861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671206861?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA31K6D5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRA","BK4139","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671026205","title":"Kailera Therapeutics Announces Completion of Enrollment in Kainetic Global Phase 3 Clinical Program of Glp-1/Gip Receptor Dual Agonist Ribupatide Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2671026205","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671026205?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:00","pubTimestamp":1790766000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nTUA31K6D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OZEM","KLRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607217","title":"Kailera Therapeutics to Join Bernstein Insights Healthcare Investor Forum Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607217?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556482,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics to join Bernstein Insights healthcare investor forum fireside chatKailera Therapeutics will join Bernstein Insights: Healthcare Leaders and Disruptors forum on Sept. 23, 2026 at 9","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL449TLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","KLRA","SF","IE00B3QW5Z07.USD","OZEM","BK4112","IE00BKPKM429.USD","BK4588","LU0314104364.USD","IE00BN0W2W23.USD","BK4127","BCDF","SG9999014039.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BK4139","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667360705","title":"Kailera Therapeutics to Participate in September Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2667360705","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667360705?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Sept.  16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/16/3363053/0/en/kailera-therapeutics-to-participate-in-september-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OZEM","JDOC","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666125553","title":"Kailera Therapeutics CTO Nur Nicholson Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666125553","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666125553?lang=en_us&edition=fundamental","pubTime":"2026-09-10 07:23","pubTimestamp":1788996216,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics CTO Nur Nicholson files initial beneficial ownership statementKailera Therapeutics named Nur Nicholson as chief technology officer in an initial SEC ownership filing dated Aug. 31","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL2NN1R8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OZEM","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659818171","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659818171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659818171?lang=en_us&edition=fundamental","pubTime":"2026-08-13 08:10","pubTimestamp":1786579809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on P3 Health Partners (PIII) and Kailera Therapeutics...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-p3-health-partners-piii-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-p3-health-partners-piii-and-kailera-therapeutics-inc-klra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LABU","HCSG","BK4139","BK4588","BK4585","BK4196","LU0128526141.USD","PIII","BK4137","XBI","KLRA","LU0029874061.USD","XLV","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659850186","title":"Kailera Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659850186","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659850186?lang=en_us&edition=fundamental","pubTime":"2026-08-13 06:22","pubTimestamp":1786573367,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryKailera Therapeutics IncKLRA.OQreported a quarterly adjusted loss of $1.09 per share for the quarter ended June","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N4492B4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRA","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188516","title":"Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188516","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188516?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:39","pubTimestamp":1786567145,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61160351/kailera-therapeutics-q2-eps-1-09-misses-0-74-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659074999","title":"Kailera Q2 FY26 Net Loss Widens to $111.31 Million; R&D Expenses Climb to $101.06 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659074999","media":"Reuters","labels":["executive","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659074999?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565148,"startTime":"0","endTime":"0","summary":"Kailera Q2 FY26 net loss widens to $111.31 million; R&D expenses climb to $101.06 millionKailera posted a net loss of USD 111.31 million, widening from USD 28.95 million a year earlier.R&D expenses mo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDLbzlZ13:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","KLRA","NDAQ","IE00BN0W2T93.GBP","SG9999014039.USD","LU0314104364.USD","BK4588","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BCDF","LU2210150020.SGD","OZEM","LU2095319765.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659670188","title":"Kailera Therapeutics - Phase 2B High-Dose Ribupatide Injection Trial Fully Enrolled; Data Expected Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659670188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659670188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659605188","title":"Kailera Therapeutics - Ind Application for Ribupatide Oral Active with FDA; Phase 3 Obesity Trials Planned First Half 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2659605188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659605188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OZEM","KLRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659290711","title":"Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659290711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659290711?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUA2YC1DX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRA","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992804","title":"Kailera Therapeutics Names Nur Nicholson Chief Technology Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992804","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992804?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:05","pubTimestamp":1786446310,"startTime":"0","endTime":"0","summary":"Kailera Therapeutics names Nur Nicholson chief technology officerKailera Therapeutics named Nur Nicholson chief technology officer, effective Aug. 31, 2026.Role centers on scaling manufacturing and su","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL2PFshn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014039.USD","BK4532","IE00BGHQF748.EUR","IE00B19Z9Z06.USD","LU0314104364.USD","BCDF","BK4588","OZEM","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014021.USD","LU0320765992.SGD","SG9999014005.SGD","SG9999014013.SGD","BK4585","BK4533","IE00B894F039.SGD","IE00B19Z9P08.USD","LU0109394709.USD","NDAQ","BK4112","IE00B3QW5Z07.USD","KLRA","BMED","BIIB","IE00BN0W2W23.USD","LU2210149790.SGD","PBE","IE00BN0W2V16.EUR","LU0889565916.HKD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kailera.com","stockEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":-0.1091},{"period":"3month","weight":-0.3791},{"period":"6month","weight":-0.5296},{"period":"1year","weight":-0.2856},{"period":"ytd","weight":-0.2856}],"compareEarnings":[{"period":"1week","weight":-0.0149},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.0243},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.1537},{"period":"ytd","weight":0.124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kailera Therapeutics, Inc. was incorporated under the laws of Delaware on May 8, 2024. The company is a clinical-stage biotechnology company dedicated to ushering in a new era of obesity treatment through the advancement of a diversified R&D pipeline. It is currently rapidly advancing four clinical-stage product candidates that leverage multiple glucagon-like peptide-1 (GLP-1)-based mechanisms of action and routes of administration.","exchange":"NASDAQ","name":"Kailera Therapeutics","nameEN":"Kailera Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kailera Therapeutics(KLRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kailera Therapeutics(KLRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kailera Therapeutics,KLRA,Kailera Therapeutics股票,Kailera Therapeutics股票老虎,Kailera Therapeutics股票老虎国际,Kailera Therapeutics行情,Kailera Therapeutics股票行情,Kailera Therapeutics股价,Kailera Therapeutics股市,Kailera Therapeutics股票价格,Kailera Therapeutics股票交易,Kailera Therapeutics股票购买,Kailera Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kailera Therapeutics(KLRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kailera Therapeutics(KLRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}